top of page

Cochlear-Oticon merger inquiry

  • Writer: DT Economics
    DT Economics
  • Dec 21, 2022
  • 1 min read

Our managing partner, David Thomas, was today appointed to the Phase 2 inquiry group for this anticipated merger in the hearing implant sector.

The CMA has referred the anticipated acquisition by Cochlear Limited of the hearing implants business of Demant A/S, known as Oticon Medical, for an in-depth investigation. This assessment will identify whether this merger has resulted, or could result, in a substantial lessening of competition within a market or markets in the United Kingdom.





Further details on the CMA's case page:






Comentários


bottom of page